DYRK1A modulates c-MET in pancreatic ductal adenocarcinoma to drive tumour growth

J Luna, J Boni, M Cuatrecasas, X Bofill-De Ros… - Gut, 2019 - gut.bmj.com
Background and aims Pancreatic ductal adenocarcinoma (PDAC) is a very aggressive
tumour with a poor prognosis using current treatments. Targeted therapies may offer a new …
被引用次数：64 相关文章

DYRK1A modulates c-MET in pancreatic ductal adenocarcinoma to drive tumour growth

J Luna, J Boni, M Cuatrecasas, X Bofill-De Ros… - Gut, 2018 - cir.nii.ac.jp
抄録< jats: sec>< jats: title> Background and aims</jats: title>< jats: p> Pancreatic ductal
adenocarcinoma (PDAC) is a very aggressive tumour with a poor prognosis using current …

DYRK1A modulates c-MET in pancreatic ductal adenocarcinoma to drive tumour growth.

J Luna, J Boni, M Cuatrecasas, X Bofill-De Ros… - Gut, 2018 - europepmc.org
Design We analysed DYRK1A expression in PDAC genetic mouse models and in patient
samples. DYRK1A function was assessed with knockdown experiments in pancreatic …

DYRK1A modulates c-MET in pancreatic ductal adenocarcinoma to drive tumour growth

J Luna, J Boni, M Cuatrecasas, X Bofill-De Ros… - Gut, 2019 - search.proquest.com
Design We analysed DYRK1A expression in PDAC genetic mouse models and in patient
samples. DYRK1A function was assessed with knockdown experiments in pancreatic …
[PDF] google.com

[PDF][PDF] DYRK1A modulates c-MET in pancreatic ductal adenocarcinoma to drive tumour growth

J Luna, J Boni, M Cuatrecasas, X Bofill-De Ros… - Gut, 2019 - drive.google.com
AbsTrACT background and aims Pancreatic ductal adenocarcinoma (PDac) is a very
aggressive tumour with a poor prognosis using current treatments. targeted therapies may …

DYRK1A modulates c-MET in pancreatic ductal adenocarcinoma to drive tumour growth

J Luna, J Boni, M Cuatrecasas, BD Ros… - 2019 - digital.csic.es
[Background and aims]: Pancreatic ductal adenocarcinoma (PDAC) is a very aggressive
tumour with a poor prognosis using current treatments. Targeted therapies may offer a new …

DYRK1A modulates c-MET in pancreatic ductal adenocarcinoma to drive tumour growth

J Luna, J Boni, M Cuatrecasas, X Bofill-De Ros… - Gut, 2018 - gut.bmj.com
Background and aims Pancreatic ductal adenocarcinoma (PDAC) is a very aggressive
tumour with a poor prognosis using current treatments. Targeted therapies may offer a new …

DYRK1A modulates c-MET in pancreatic ductal adenocarcinoma to drive tumour growth

J Luna, J Boni, M Cuatrecasas, X Bofill-De Ros… - Gut, 2019 - pubmed.ncbi.nlm.nih.gov
Background and aims Pancreatic ductal adenocarcinoma (PDAC) is a very aggressive
tumour with a poor prognosis using current treatments. Targeted therapies may offer a new …